… We utilized secondary prevention drug information that was provided at the last follow-up
visit (vs baseline visit approach) because (1) the number and type of secondary prevention …

… of cardiovascular secondary prevention evaluation. Use of incomplete drugs combinations
compared with the recommended four drugs combination in secondary prevention of ACS …

… -ACS cardiovascular secondary prevention drug treatment in France was not optimal,
particularly in patients without AMI. This could help target future research into drug effectiveness in …

… Here we focus in particular on secondary prevention in the context of ischemic heart
disease… The efficacy of cardiovascular drugs in secondary prevention is also limited by poor …

… characteristics are minimised for the secondary prevention cohort (see supplementary table
… daily arm of the RE-LY study in combination with data from ARISTOTLE and ROCKET-AF to …

… drugs tested in randomized trials (eg diuretics, CCBs [47], and fibrates [48]), a lack of conclusive
evidence of benefits for some drugs on the secondary prevention … valsartan combination. …

… drug classes may offer a statistically significant, albeit clinically marginal, benefit in the primary
and secondary prevention of … Thus, the best drug or combination of drugs for an individual …

… secondary prevention therapies (ACEIs or ARBs, beta-blockers, and statins) alone and in
combination … rates of use of the following secondary prevention therapies in patients with ACS …

… to characterize the factors that underlie inadequate secondary prevention and to test a
new FDC. … potentially related to lack of adequate secondary prevention in 4,000 post–myocardial …

… Results: Between 1994 and 2005 use of drugs for secondary prevention increased markedly.
By 2005, 80% of men and 70% of women were receiving a statin, 75% and 74% were …